Cargando…

Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer

In this study, we aimed to investigate the feasibility of serum Krebs von den Lungen-6 (KL-6) as a potential biomarker for treatment-related ILD (TR-ILD) in lung cancer. We recruited patients with lung cancer in whom KL-6 was measured to differentiate between pneumonia and ILD (category 1), diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hwa Kyung, Yoon, Chang-Seok, Na, Young-Ok, Lee, Jae-Kyeong, Oh, Hyung-Joo, Park, Ha-Young, Kho, Bo-Gun, Kim, Tae-Ok, Shin, Hong-Joon, Kwon, Yong-Soo, Oh, In-Jae, Kim, Yu-Il, Lim, Sung-Chul, Kim, Young-Chul, Park, Cheol-Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593856/ https://www.ncbi.nlm.nih.gov/pubmed/37872370 http://dx.doi.org/10.1038/s41598-023-45170-8

Ejemplares similares

Risk factors for cerebral complications in patients with pulmonary arteriovenous malformations: A multicenter retrospective cohort study
por: Na, Young-Ok, et al.
Publicado: (2022)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Delayed diagnosis of lung cancer due to misdiagnosis as worsening of sarcoidosis: a case report
por: Shin, Hong-Joon, et al.
Publicado: (2020)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
por: Park, Ha-Young, et al.
Publicado: (2019)

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Life-threatening Mycobacterium intracellulare pleuritis in an immunocompetent host: Case reports
por: Kho, Bo-Gun, et al.
Publicado: (2021)

Usefulness of Mycobacterium tuberculosis-polymerase chain reaction with bronchial washing samples in predicting discontinuation of airborne infection isolation in patients hospitalized with suspected pulmonary tuberculosis
por: Kim, Tae-Ok, et al.
Publicado: (2022)

Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
por: Kim, Tae‐Ok, et al.
Publicado: (2018)

Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness
por: Kim, Tae-Ok, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
por: Park, Seongho, et al.
Publicado: (2019)

Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis
por: Lee, Jae-Kyeong, et al.
Publicado: (2022)

Myasthenia gravis and myopathy after nivolumab treatment for non‐small cell lung carcinoma: A case report
por: Kim, Je‐Seong, et al.
Publicado: (2019)

Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019)

Potentially fatal complications of systemic air embolism after computed tomography‐guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report
por: Oh, Hyung‐Joo, et al.
Publicado: (2020)

Glutathione Peroxidase 3 as a Biomarker of Recurrence after Lung Cancer Surgery
por: Kho, Bo Gun, et al.
Publicado: (2020)

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2021)

Collaborative Care to Relieve Psychological Distress in Patients with Medically Inoperable Lung Cancer: Design and Rationale for a Clinical Trial
por: Kim, Seon-Young, et al.
Publicado: (2019)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
por: Park, Cheol Kyu, et al.
Publicado: (2017)

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
por: Park, Cheol-Kyu, et al.
Publicado: (2021)

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Hypersensitivity reactions to multiple anti-tuberculosis drugs
por: Shin, Hong-Joon, et al.
Publicado: (2021)

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Prognostic role of blood KL-6 in rheumatoid arthritis–associated interstitial lung disease
por: Kim, Ho Cheol, et al.
Publicado: (2020)

Blood KL-6 predicts prognosis in primary Sjögren’s syndrome-associated interstitial lung disease
por: Kim, Yun Jae, et al.
Publicado: (2022)

What is Currently the Best for Adenocarcinoma without Driver Mutation?
por: Park, Cheol-Kyu, et al.
Publicado: (2018)

Superior vena cava syndrome with extensive collateral vessels
por: Oh, In‐Jae, et al.
Publicado: (2019)

Efficacy of an inpatient smoking cessation program at a single regional cancer center: A prospective observational study
por: Park, Ha-Young, et al.
Publicado: (2021)

Does Hypercapnic Acidosis, induced by Adding CO(2) to Inspired Gas, Have Protective Effect in a Ventilator-induced Lung Injury?
por: Park, Chang Min, et al.
Publicado: (2005)

Pulmonary sclerosing pneumocytoma mimicking lung cancer: Case report and review of the literature
por: Lim, Jung‐Hwan, et al.
Publicado: (2016)

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
por: Yoon, Seong-Hoon, et al.
Publicado: (2015)

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
por: Park, Cheol‐Kyu, et al.
Publicado: (2020)

A Comparison of Serum CYFRA 21-1 and SCC Ag in the Diagnosis of Squamous Cell Lung Carcinoma
por: Kim, Young-Chul, et al.
Publicado: (1996)

DNA Ploidy and Proliferative Activity in bcl-2 Expressed Non-small Cell lung Cancer
por: Kim, Young-Chul, et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_u2l9tcpj7rjm7vlouqju8trvq9